Efficacy and safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF)[1](ASCEND). ClinicalTrials.gov. Retrieved 2013-04-11. Gearchiveerd op 31 juli 2023.
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients.[3] ClinicalTrials.gov. Retrieved 2013-04-11. Gearchiveerd op 31 juli 2023.
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II.[4] ClinicalTrials.gov. Retrieved 2013-04-11. Gearchiveerd op 31 juli 2023.
doi.org
doi.org
Raghu G, Collard HR, Egan JJ, et al (2011). An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am. J Respir. Crit. Care Med.183 (6): 788–824. PMID21471066. DOI: 10.1164/rccm.2009-040GL.
Loomis-King H, Flaherty KR, Moore BB (April 2013). Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis. Current Opinion in Pharmacology13 (3): 377–385. DOI: 10.1016/j.coph.2013.03.015.
Selman M, King TE, Pardo A (2001). Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Annals of Internal Medicine134 (2): 136–151. PMID11177318. DOI: 10.7326/0003-4819-134-2-200101160-00015.
Flaherty KR, King TE, Raghu G, Lynch JP, Colby TV, Travis WD, Gross BH, Kazerooni EA, et al. (2004). Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?. Am J Respir Crit Care Med.170 (8): 904–910. PMID15256390. DOI: 10.1164/rccm.200402-147OC.
Flaherty KR, Andrei AC, King TE Jr, Raghu G, Colby TV, Wells A, Bassily N, Brown K, et al. (2007). Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?. Am J Respir Crit Care Med.175 (10): 1054–1060. PMID17255566. PMC1899268. DOI: 10.1164/rccm.200606-833OC.
Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, Travis WD, Flint A, et al. (2007). Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med.168 (5): 543–548. PMID12773329. DOI: 10.1164/rccm.200209-1112OC.
Cottin V, Cordier JF (2012). Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis. Eur Respir J.40 (3): 519–521. PMID22941541. DOI: 10.1183/09031936.00001612.
Ohshimo S, Bonella F, Cui A, Beume M, Kohno N, Guzman J, Costabel U (2009). Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med.179 (11): 1043–1047. DOI: 10.1164/rccm.200808-1313oc.
Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE, Lancaster L, et al. (2011). Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet377 (9779): 1760–1769. PMID21571362. DOI: 10.1016/S0140-6736(11)60405-4.
Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, Flaherty KR, Schwartz DA, et al. IPF study group (2005). The clinical course of patients with idiopathic pulmonary fibrosis. Annals of Internal Medicine377 (9779): 1760–1769. PMID21571362. DOI: 10.1016/S0140-6736(11)60405-4.
Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, Offord KP (1998). Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med.157 (1): 199–203. PMID9445300. DOI: 10.1164/ajrccm.157.1.9704130.
Kim DS, Collard HR, King TE (2006). Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc.3 (4): 285–292. PMID16738191. PMC2658683. DOI: 10.1513/pats.200601-005TK.
Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE Jr, Collard HR. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Annals of Internal Medicine156 (10): 684–691. DOI: 10.7326/0003-4819-156-10-201205150-00004.
Lee JS, McLaughlin S, Collard HR (2011). Comprehensive care of the patient with idiopathic pulmonary fibrosis. Current Opinion in Pulmonary Medicine17 (5): 348–354. DOI: 10.1097/mcp.0b013e328349721b.
King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, et al. INSPIRE Study Group (2009). Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis. Lancet374 (9685): 222–228. PMID19570573. DOI: 10.1016/S0140-6736(09)60551-1.
King TE Jr, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, Valeyre D, Leconte I, et al. (2011). BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med.184 (1): 92–99. PMID21474646. DOI: 10.1164/rccm.201011-1874OC.
Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Nathan SD, et al. (2013). Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Annals of Internal Medicine158 (9): 641–649. PMID23648946. DOI: 10.7326/0003-4819-158-9-201305070-00003.
Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, Kaner RJ, Olman MA (2012). Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet) A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med.186 (1): 88–95. PMID22561965. DOI: 10.1164/rccm.201202-0314OC.
Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K (2011). Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev.20 (120): 85–97. PMID21632796. DOI: 10.1183/09059180.00001111.
Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, et al. (2010). Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J.35 (4): 821–829. PMID19996196. DOI: 10.1183/09031936.00005209.
de Bois RM, Weycker D, Albera C, et al. (2011). Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med.184 (4): 459/466. PMID21616999. DOI: 10.1164/rccm.201011-1790OC.
King TE Jr1, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW; ASCEND Study Group (2014). A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med.370 (22): 2083–92. PMID24836312. DOI: 10.1056/NEJMoa1402582.
Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, et al. (2005). High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med.353 (21): 2229–2242. PMID16306520. DOI: 10.1056/NEJMoa042976.
Idiopathic Pulmonary Fibrosis Clinical Research Network, Martinez FJ, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G. (2014). Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med370 (22): 2093–101. PMID24836309. DOI: 10.1056/NEJMoa1401739.
Behr J. (2012). Prednisone, azathioprine an N-acetylcysteine for pulmonary fibrosis. N Engl J Med.367 (9): 869–871. PMID22931324. DOI: 10.1056/NEJMc1207471.
Spagnolo P, Tonelli R, Cocconcelli E, Stefani A, Richeldi L (2012). Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges. Multidiscip Respir Med.7 (1). DOI: 10.1186/2049-6958-7-42.
Lee JS, McLaughlin S, Collard HR (2011). Comprehensive care of the patient with idiopathic pulmonary fibrosis. Current Opinion in Pulmonary Medicine17 (5): 348–354. DOI: 10.1097/mcp.0b013e328349721b.
Kenn, K, Gloeckl, R, Behr, J (2013). Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis--a review.. Respiration; international review of thoracic diseases86 (2): 89–99. PMID23942353. DOI: 10.1159/000354112.
Allen S, Raut S, Woollard J, Vassallo M (2005). Low dose diamorphine reduces breathlessness without causing a fall in oxygen saturation in elderly patients with end-stage idiopathic pulmonary fibrosis. Palliat Med.19 (2): 128–130. DOI: 10.1191/0269216305pm998oa.
Agarwal R, Jindal SK (2008). Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review. Eur J Intern Med.19 (4): 227–235. DOI: 10.1016/j.ejim.2007.04.024.
Raghu G, Collard HR, Egan JJ, et al (2011). An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am. J Respir. Crit. Care Med.183 (6): 788–824. PMID21471066. DOI: 10.1164/rccm.2009-040GL.
American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am Respir Crit Care Med. 165 (2) 277–304. January 2002. PMID11790668
Selman M, King TE, Pardo A (2001). Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Annals of Internal Medicine134 (2): 136–151. PMID11177318. DOI: 10.7326/0003-4819-134-2-200101160-00015.
Flaherty KR, King TE, Raghu G, Lynch JP, Colby TV, Travis WD, Gross BH, Kazerooni EA, et al. (2004). Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?. Am J Respir Crit Care Med.170 (8): 904–910. PMID15256390. DOI: 10.1164/rccm.200402-147OC.
Flaherty KR, Andrei AC, King TE Jr, Raghu G, Colby TV, Wells A, Bassily N, Brown K, et al. (2007). Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?. Am J Respir Crit Care Med.175 (10): 1054–1060. PMID17255566. PMC1899268. DOI: 10.1164/rccm.200606-833OC.
Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, Travis WD, Flint A, et al. (2007). Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med.168 (5): 543–548. PMID12773329. DOI: 10.1164/rccm.200209-1112OC.
Cottin V, Cordier JF (2012). Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis. Eur Respir J.40 (3): 519–521. PMID22941541. DOI: 10.1183/09031936.00001612.
Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE, Lancaster L, et al. (2011). Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet377 (9779): 1760–1769. PMID21571362. DOI: 10.1016/S0140-6736(11)60405-4.
Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, Flaherty KR, Schwartz DA, et al. IPF study group (2005). The clinical course of patients with idiopathic pulmonary fibrosis. Annals of Internal Medicine377 (9779): 1760–1769. PMID21571362. DOI: 10.1016/S0140-6736(11)60405-4.
Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, Offord KP (1998). Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med.157 (1): 199–203. PMID9445300. DOI: 10.1164/ajrccm.157.1.9704130.
Kim DS, Collard HR, King TE (2006). Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc.3 (4): 285–292. PMID16738191. PMC2658683. DOI: 10.1513/pats.200601-005TK.
King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, et al. INSPIRE Study Group (2009). Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis. Lancet374 (9685): 222–228. PMID19570573. DOI: 10.1016/S0140-6736(09)60551-1.
King TE Jr, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, Valeyre D, Leconte I, et al. (2011). BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med.184 (1): 92–99. PMID21474646. DOI: 10.1164/rccm.201011-1874OC.
Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Nathan SD, et al. (2013). Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Annals of Internal Medicine158 (9): 641–649. PMID23648946. DOI: 10.7326/0003-4819-158-9-201305070-00003.
Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, Kaner RJ, Olman MA (2012). Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet) A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med.186 (1): 88–95. PMID22561965. DOI: 10.1164/rccm.201202-0314OC.
Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K (2011). Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev.20 (120): 85–97. PMID21632796. DOI: 10.1183/09059180.00001111.
Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, et al. (2010). Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J.35 (4): 821–829. PMID19996196. DOI: 10.1183/09031936.00005209.
Spagnolo P, Del Giovane C, Luppi F, Cerri S, Balduzzi S, Walters EH, D'Amico R, Richeldi L (2010). "Non-steroid agents for idiopathic pulmonary fibrosis". Cochrane Database Syst Rev. (9) CD003134. DOI:10.1002/14651858.CD003134.pub2PMID20824834
de Bois RM, Weycker D, Albera C, et al. (2011). Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med.184 (4): 459/466. PMID21616999. DOI: 10.1164/rccm.201011-1790OC.
King TE Jr1, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW; ASCEND Study Group (2014). A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med.370 (22): 2083–92. PMID24836312. DOI: 10.1056/NEJMoa1402582.
Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, et al. (2005). High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med.353 (21): 2229–2242. PMID16306520. DOI: 10.1056/NEJMoa042976.
Idiopathic Pulmonary Fibrosis Clinical Research Network, Martinez FJ, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G. (2014). Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med370 (22): 2093–101. PMID24836309. DOI: 10.1056/NEJMoa1401739.
Behr J. (2012). Prednisone, azathioprine an N-acetylcysteine for pulmonary fibrosis. N Engl J Med.367 (9): 869–871. PMID22931324. DOI: 10.1056/NEJMc1207471.
Efficacy and safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF)[1](ASCEND). ClinicalTrials.gov. Retrieved 2013-04-11. Gearchiveerd op 31 juli 2023.
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients.[3] ClinicalTrials.gov. Retrieved 2013-04-11. Gearchiveerd op 31 juli 2023.
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II.[4] ClinicalTrials.gov. Retrieved 2013-04-11. Gearchiveerd op 31 juli 2023.
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF).[5] ClinicalTrials.gov. Retrieved 2013-04-11.
Canine Pulmonary Fibrosis.[6] Akcchf.org. Retrieved 2013-04-11. Gearchiveerd op 23 januari 2023.
